Changes for page Neurodiagnoses

Last modified by manuelmenendez on 2025/03/03 22:46
From version 9.1
edited by manuelmenendez
on 2025/01/27 23:23
Change comment: There is no comment for this version
To version 7.1
edited by manuelmenendez
on 2025/01/27 23:21
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -15,7 +15,7 @@
15 15  (((
16 16  = What is this about and what can I find here? =
17 17  
18 -== **Overview** ==
18 +==== **Overview** ====
19 19  
20 20  The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDDs) are classified by focusing on:
21 21  
... ... @@ -29,7 +29,7 @@
29 29  * Integration of incomplete datasets using AI-driven probabilistic modeling.
30 30  * Stratification of patients for personalized treatment.
31 31  
32 -== **Diagnostic Axes** ==
32 +==== **Diagnostic Axes** ====
33 33  
34 34  * (((
35 35  **Axis 1: Etiology**
... ... @@ -53,11 +53,28 @@
53 53  * //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
54 54  )))
55 55  
56 -== **Applications** ==
56 +==== **Case Studies** ====
57 57  
58 +1. (((
59 +**Sporadic Alzheimer’s Disease**:
60 +
61 +* Axis 1: Sporadic (ApoE4, poor sleep habits).
62 +* Axis 2: Amyloid-beta plaques, elevated NFL.
63 +* Axis 3: Right hippocampus atrophy (visual memory loss).
64 +)))
65 +1. (((
66 +**Genetic Parkinson’s Disease**:
67 +
68 +* Axis 1: Genetic (LRRK2 mutation).
69 +* Axis 2: Alpha-synuclein aggregation.
70 +* Axis 3: Substantia nigra degeneration (motor dysfunction).
71 +)))
72 +
73 +==== **Applications** ====
74 +
58 58  This system enhances:
59 59  
60 -* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
77 +* **Research**: By stratifying patients, it reduces cohort heterogeneity in clinical trials.
61 61  * **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
62 62  
63 63  == Who has access? ==